PNC Financial Services Group Inc. Purchases 8,463 Shares of Genmab A/S (NASDAQ:GMAB)

PNC Financial Services Group Inc. increased its position in shares of Genmab A/S (NASDAQ:GMAB) by 5.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 165,187 shares of the company’s stock after purchasing an additional 8,463 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Genmab A/S were worth $5,260,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Pinnacle Bancorp Inc. lifted its holdings in shares of Genmab A/S by 315.8% in the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after acquiring an additional 638 shares during the last quarter. Principal Securities Inc. bought a new position in shares of Genmab A/S in the fourth quarter worth about $77,000. Advisors Preferred LLC bought a new position in shares of Genmab A/S in the fourth quarter worth about $82,000. Exchange Traded Concepts LLC lifted its holdings in shares of Genmab A/S by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 3,691 shares of the company’s stock worth $118,000 after acquiring an additional 936 shares during the last quarter. Finally, Barometer Capital Management Inc. acquired a new position in shares of Genmab A/S in the fourth quarter valued at approximately $121,000. Institutional investors own 7.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on GMAB shares. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Monday, June 3rd. BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $46.00 to $48.00 in a research report on Friday, February 23rd. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a research report on Tuesday, March 26th. Finally, Truist Financial raised their price objective on shares of Genmab A/S from $50.00 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, June 4th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $49.25.

Genmab A/S Trading Up 0.1 %

Shares of NASDAQ:GMAB opened at $25.80 on Wednesday. The stock has a market cap of $17.06 billion, a PE ratio of 21.50, a price-to-earnings-growth ratio of 0.95 and a beta of 0.99. Genmab A/S has a 1-year low of $25.38 and a 1-year high of $42.72. The stock’s fifty day simple moving average is $28.51 and its two-hundred day simple moving average is $29.43.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, May 2nd. The company reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. The company had revenue of $603.30 million for the quarter, compared to analysts’ expectations of $594.23 million. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. On average, sell-side analysts forecast that Genmab A/S will post 1.11 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.